Biotech entity
Every one of those 1 sits in a single category, pharma. AI Antidote Development Model is the most frequent co-covered peer, appearing in 1 of the 1 tracked story. The 7 average consequence score is above the beat benchmark of 6 in the same window.
Last mentioned: Mar 19, 2026
Entity pulse
Coverage balance Positive coverage leads. Positive coverage exceeds negative coverage by 100 percentage points.
Figures are computed live from our source-verified story record — see our methodology for how impact and sentiment are derived.
Every one of those 1 sits in a single category, pharma. AI Antidote Development Model is the most frequent co-covered peer, appearing in 1 of the 1 tracked story. The 7 average consequence score is above the beat benchmark of 6 in the same window. Source depth averages 2 original sources per story, versus 2.6 across the same-window beat baseline. Lunai Bioworks appears in 1 tracked Biotech story from March 19, 2026.
Computed from the 1 stories linked to this entity, with beat comparisons drawn from all 23 Biotech stories published in the same date window. Shares are omitted below five stories and comparisons below a twenty-story baseline.
Coverage cohort
Other entities that clear the same relevance threshold in stories also covering Lunai Bioworks. Shared-story counts are live from our verified record — not editorial picks.
Consortium Launch
Lunai Bioworks officially announces the National Chemical Defense Consortium.
Lunai Bioworks (NASDAQ: LNAI) has established the National Chemical Defense Consortium to target U.S. government countermeasure contracts valued up to $1.2 billion. The initiative leverages a proprietary three-year AI-driven development model to accelerate the creation of antidotes for chemical threats.
Lunai Bioworks is linked from 1 story on this site, each scored at or above our 35% relevance threshold — see how these pages are built.
See something wrong on this page — a misattributed entity, a wrong stat, a broken source link? Report a data issue.
